中度混合性主动脉瓣病变患者的结局预测因素
本研究基于多中心注册数据,纳入207例中度混合性主动脉瓣病变(MAVD)患者,评估其预后血流动力学标志物。中位随访3.5年,43%患者发生死亡或心衰住院复合终点。校正后主动脉峰值流速(Vmax)与复合终点独立负相关(HR 0.63),Vmax≤2.8 m/s且LVEF≤50%者结局最差(72% vs 41%,HR 3.87)。
要点
- 中度MAVD患者3.5年死亡或心衰住院复合终点发生率达43%。
- Vmax较高与复合终点风险降低独立相关(HR 0.63,95%CI 0.43–0.93)。
- Vmax≤2.8 m/s且LVEF≤50%者复合终点风险显著增高(HR 3.87)。
核心结论
- 真正中度MAVD患者死亡和心衰住院发生率高,3.5年复合终点达43%。
- Vmax≤2.8 m/s且LVEF≤50%的患者结局最差,构成高危亚组。
研究设计与样本
- 多中心注册研究,纳入2015至2019年连续诊断的中度MAVD患者207例。
- 中度MAVD定义为并存中度主动脉瓣狭窄(AVA 1.0–1.5 cm²)和中度主动脉瓣反流(VC 0.3–0.6 cm)。
- 评估 demographics、合并症、超声心动图和治疗数据对预后的意义。
主要发现
- 患者年龄78(66–84)岁,56%为男性,AVA 1.2(1.1–1.4)cm²,VC 0.4(0.4–0.5)cm。
- 随访3.5(2.5–4.7)年,89例(43%)达到主要复合终点。
- 多变量分析中Vmax与复合终点独立负相关(HR 0.63,95%CI 0.43–0.93;p=0.021)。
- 年龄(HR 1.05,95%CI 1.03–1.08;p<0.001)、肌酐(HR 1.002,95%CI 1.001–1.003;p=0.005)、既往脑血管事件(85% vs 42%;HR 3.04,95%CI 1.54–5.99;p=0.001)和LVEF(HR 0.97,95%CI 0.95–0.99;p=0.007)亦与复合终点独立相关。
- Vmax≤2.8 m/s且LVEF≤50%者(n=27)复合终点发生率72%,其余人群41%(HR 3.87,95%CI 2.20–6.80;p<0.001)。
关键数值与推荐
- 中度MAVD定义:AVA 1.0–1.5 cm²且VC 0.3–0.6 cm。
- 高危亚组标准:Vmax≤2.8 m/s且LVEF≤50%。
临床怎么用
- 对中度MAVD患者应关注Vmax和LVEF,识别Vmax≤2.8 m/s且LVEF≤50%的高危患者。
- 高危患者可能需要更密切随访和考虑更早干预,但需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Grading the severity of moderate mixed aortic stenosis and regurgitation (MAVD) is challenging and the disease poorly understood. Identifying markers of haemodynamic severity will improve risk stratification and potentially guide timely treatment. This study aims to identify prognostic haemodynamic markers in patients with moderate MAVD. METHODS: Moderate MAVD was defined as coexisting moderate aortic stenosis (aortic valve area (AVA) 1.0-1.5 cm2) and moderate aortic regurgitation (vena contracta (VC) 0.3-0.6 cm). Consecutive patients diagnosed between 2015 and 2019 were included from a multicentre registry. The primary composite outcome of death or heart failure hospitalisation was evaluated among these patients. Demographics, comorbidities, echocardiography and treatment data were assessed for their prognostic significance. RESULTS: 207 patients with moderate MAVD were included, aged 78 (66-84) years, 56% male sex, AVA 1.2 (1.1-1.4) cm2 and VC 0.4 (0.4-0.5) cm. Over a follow-up of 3.5 (2.5-4.7) years, the composite outcome was met in 89 patients (43%). Univariable associations with the primary outcome included older age, previous myocardial infarction, previous cerebrovascular event, atrial fibrillation, New York Heart Association >2, worse renal function, tricuspid regurgitation ≥2 and mitral regurgitation ≥2. Markers of biventricular systolic function, cardiac remodelling and transaortic valve haemodynamics demonstrated an inverse association with the primary composite outcome. In multivariable analysis, peak aortic jet velocity (Vmax) was independently and inversely associated with the composite outcome (HR: 0.63, 95% CI 0.43 to 0.93; p=0.021) in an adjusted model along with age (HR: 1.05, 95% CI 1.03 to 1.08; p<0.001), creatinine (HR: 1.002, 95% CI 1.001 to 1.003; p=0.005), previous cerebrovascular event (85% vs 42%; HR: 3.04, 95% CI 1.54 to 5.99; p=0.001) and left ventricular ejection fraction (LVEF) (HR: 0.97, 95% CI 0.95 to 0.99; p=0.007). Patients with Vmax ≤2.8 m/s and LVEF ≤50% (n=27) had the worst outcome compared with the rest of the population (72% vs 41%; HR: 3.87, 95% CI 2.20 to 6.80; p<0.001). CONCLUSIONS: Patients with truly moderate MAVD have a high incidence of death and heart failure hospitalisation (43% at 3.5 (2.5-4.7) years). Within this group, a high-risk group characterised by disproportionately low aortic Vmax (≤2.8 m/s) and adverse remodelling (LVEF ≤50%) have the worst outcomes.
引用
- Patel KP, McKenna M, Thornton GD, et al. Predictors of outcome in patients with moderate mixed aortic valve disease. Heart. 2024. PMID: 38148159. doi:10.1136/heartjnl-2023-323321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。